Cellumed Co Ltd
KOSDAQ:049180
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cellumed Co Ltd
Total Equity
Cellumed Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cellumed Co Ltd
KOSDAQ:049180
|
Total Equity
₩8.4B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-15%
|
|
|
I
|
I Sens Inc
KOSDAQ:099190
|
Total Equity
₩315.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
C
|
Classys Inc
KOSDAQ:214150
|
Total Equity
₩553B
|
CAGR 3-Years
34%
|
CAGR 5-Years
35%
|
CAGR 10-Years
49%
|
|
|
W
|
Won Tech Co Ltd
KOSDAQ:336570
|
Total Equity
₩126.8B
|
CAGR 3-Years
129%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
V
|
Viol Co Ltd
KOSDAQ:335890
|
Total Equity
₩88.8B
|
CAGR 3-Years
50%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
S
|
Seers Technology Co Ltd
KOSDAQ:458870
|
Total Equity
₩21.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cellumed Co Ltd
Glance View
CELLUMED Co., Ltd. engages in the manufacture and distribution of medical device and biomaterials. The company is headquartered in Seoul, Seoul. The company went IPO on 2002-05-23. The Company’s products consist of allografts for tissue repair; bone sponges, bone powders and demineralized bone matrixes (DBMs) for bone regeneration; biosimilars, such as bone morphogenetic protein 2 (BMP2) reagents and others, as well as medical devices, such as spinal fixation systems, joint replacements and navigation systems. The firm sells its products within domestic market and to overseas markets.
See Also
What is Cellumed Co Ltd's Total Equity?
Total Equity
8.4B
KRW
Based on the financial report for Dec 31, 2025, Cellumed Co Ltd's Total Equity amounts to 8.4B KRW.
What is Cellumed Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
-15%
Over the last year, the Total Equity growth was -5%. The average annual Total Equity growth rates for Cellumed Co Ltd have been -46% over the past three years , -21% over the past five years , and -15% over the past ten years .
